Finance

Beta
Lists
9II:FRA
Biovica International AB
€0.012
0.00%
(0.00) 1D
Jul 2, 9:08:17 AM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for 9II...
Mkt. cap
101.53M
Avg. vol.
90.00
Volume
0.00
52-wk high
€0.05
52-wk low
€0.00
No. of employees
25
Mkt. cap
101.53M
Avg. vol.
90.00
Volume
0.00
52-wk high
€0.05
52-wk low
€0.00
No. of employees
25
News stories
From sources across the web
About Biovica International AB
CEO-
Employees25
Founded2008
Headquarters-
SectorBiotechnology
Previous reportsAll values in SEK
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in SEK
Jul 2025
Oct 2025
Jan 2026
Apr 2026
Revenue
2.60M
2.68M
3.29M
4.82M
Cost of goods sold
171.00K
-431.00K
48.00K
255.00K
Cost of revenue
171.00K
-431.00K
48.00K
255.00K
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
19.37M
16.00M
19.06M
20.66M
Operating expense
21.97M
18.17M
21.14M
22.81M
Total operating expenses
22.14M
17.74M
21.18M
23.06M
Operating income
-19.55M
-15.06M
-17.89M
-18.25M
Other non operating income
212.00K
94.00K
113.00K
206.00K
EBT including unusual items
-19.14M
-14.98M
-17.69M
-17.70M
EBT excluding unusual items
-19.14M
-14.98M
-17.69M
-17.70M
Income tax expense
-1.36M
128.00K
161.00K
1.42M
Effective tax rate
7.11%
-0.85%
-0.91%
-8.05%
Other operating expenses
462.00K
32.00K
49.00K
155.00K
Net income
-17.78M
-15.11M
-17.85M
-19.12M
Net profit margin
-685.01%
-564.69%
-541.96%
-397.13%
Earnings per share
-0.18
-0.06
-0.06
-
Interest and investment income
433.00K
56.00K
136.00K
383.00K
Interest expense
-236.00K
-74.00K
-49.00K
-37.00K
Net interest expenses
197.00K
-18.00K
87.00K
346.00K
Depreciation and amortization charges
2.14M
2.13M
2.02M
2.00M
EBITDA
-17.41M
-12.93M
-15.87M
-16.25M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more